Click on headlines below to download research
Oasmia’s H1 FY21 results highlight recent developments made to realign the business. In December, global partner Elevar Therapeutics announced it…
Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through…
Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform…